List of Excipients in Branded Drug DURAMORPH

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hikma Pharmaceuticals USA Inc	DURAMORPH	morphine sulfate	0641-6020	SODIUM CHLORIDE
Hikma Pharmaceuticals USA Inc	DURAMORPH	morphine sulfate	0641-6020	WATER

DURAMORPH Excipient Strategy and Commercial Opportunities

Last updated: October 21, 2026

DURAMORPH is a preservative-free morphine sulfate injection for epidural or intrathecal administration. Its commercial value depends less on active-ingredient exclusivity than on sterile manufacturing, neuraxial-use compatibility, presentation design, supply reliability, and hospital procurement economics. The strongest excipient strategy is conservative: preserve the low-excipient profile, avoid antimicrobial preservatives, control pH and osmolality, and differentiate through ready-to-administer packaging and validated container-closure systems.

What is DURAMORPH and how does its formulation affect commercial strategy?

DURAMORPH is an injectable morphine sulfate product intended for neuraxial administration. The FDA labeling identifies it as preservative-free and supplied in sterile single-dose presentations. Its formulation is based on morphine sulfate in Water for Injection, with sodium chloride used in applicable presentations to control tonicity [1].

Attribute	Commercial significance
Active ingredient	Morphine sulfate
Dosage form	Sterile injectable solution
Primary routes	Epidural and intrathecal; label-specific use controls apply
Preservative status	Preservative-free
Main excipient system	Water for Injection, with sodium chloride in applicable strengths
Regulatory pathway for competitors	Abbreviated New Drug Application, where sameness requirements are met
Hospital setting	Anesthesia, surgery, pain management, and inpatient care
Key quality risks	Sterility, particulate matter, extractables, adsorption, concentration errors, and neuraxial safety

The preservative-free design is central to the product’s identity. Benzyl alcohol and other antimicrobial preservatives are generally unsuitable for intrathecal administration because of neurotoxicity concerns and route-specific safety restrictions. Excipient selection therefore has a narrower operating window than for standard intravenous products.

What excipients are used in DURAMORPH?

The core formulation is intentionally simple. Public labeling identifies morphine sulfate and Water for Injection, with sodium chloride used in the formulation to achieve an appropriate injectable solution profile [1].

Excipient role and risk profile

Excipient or material	Likely function	Strategic assessment
Water for Injection	Solvent	Required for sterile parenteral manufacture
Sodium chloride	Tonicity adjustment	Established, low-risk choice for injectable products
pH adjustment system, if used	pH control	Must be justified and controlled for stability and tolerability
Container-closure materials	Product protection	May influence adsorption, leachables, and shelf life
Antimicrobial preservatives	Multidose protection	Generally inconsistent with neuraxial positioning
Antioxidants	Oxidation control	Should be avoided unless supported by degradation data and route-specific safety assessment
Chelating agents	Trace-metal control	Commercially possible but adds regulatory and toxicological burden

The formulation objective is not to maximize excipient innovation. It is to minimize avoidable variables while meeting sterility, stability, tonicity, particulate, and container-closure requirements.

What excipient strategy is appropriate for a DURAMORPH competitor?

A competitor should pursue a three-tier strategy.

Tier 1: Minimal injectable formulation

The lowest-risk approach is a morphine sulfate solution using Water for Injection and sodium chloride, with no preservative. This formulation is most compatible with an ANDA strategy if the reference product’s qualitative and quantitative composition can be matched or adequately justified.

The principal development work should cover:

• Morphine assay and related substances
• pH drift during storage
• Osmolality and injection-site tolerability
• Visible and subvisible particulate matter
• Sterility and bacterial endotoxins
• Container-closure integrity
• Light sensitivity
• Compatibility with syringes, needles, infusion components, and neuraxial administration equipment
• Adsorption to polymeric contact surfaces

Tier 2: Packaging-led differentiation

The strongest commercial opportunity may come from packaging rather than a new excipient. Options include:

• Ready-to-administer prefilled syringes
• Unit-dose ampules with clearer strength differentiation
• Low-dead-volume syringes
• Tamper-evident secondary packaging
• Barcode-enabled hospital inventory units
• Color-coded but standards-compliant strength identification
• Carton configurations optimized for automated dispensing cabinets

Packaging changes can reduce preparation steps and medication-selection errors. They also create additional regulatory and human-factors work. A prefilled syringe may require extractables and leachables testing, delivery-force testing, silicone-oil assessment, needle compatibility studies, and container-closure validation.

Tier 3: Clinically differentiated delivery

More ambitious products could include preservative-free morphine sulfate in specialized delivery formats for neuraxial or postoperative use. These products may support a 505(b)(2) strategy if they rely on a new device, route, concentration, dosing format, or administration profile rather than simple chemical sameness.

This path has higher development cost and greater regulatory risk. A new delivery system must establish dose accuracy, compatibility, sterility, usability, and clinical relevance. The commercial advantage must be visible to hospitals, anesthesiologists, and pharmacy buyers.

What formulations are protected by DURAMORPH patents?

DURAMORPH is an older morphine sulfate product, and the active ingredient is long off patent. The commercial protection for the legacy product is therefore based primarily on FDA approval, manufacturing quality, brand recognition, supply continuity, and hospital contracting rather than a current composition-of-matter patent.

Protection category	DURAMORPH assessment
Morphine sulfate composition-of-matter patent	Expired or commercially irrelevant
Original formulation patent	Any historic protection would be expected to have expired
Current Orange Book patent barrier	No material patent barrier should be assumed without a current FDA Orange Book review
Method-of-use patents	Limited relevance to an old generic-active product
Device or packaging patents	Potentially relevant only to later differentiated presentations
Trade secrets	Sterile processing, filling controls, validation, and supply-chain execution may remain important
Regulatory exclusivity	Legacy product exclusivity is not the principal commercial barrier

An entrant should not base its business case on avoiding a presumed DURAMORPH patent. It should instead assess whether the proposed product is an ANDA-equivalent injectable or a differentiated 505(b)(2) product.

When does DURAMORPH lose exclusivity?

DURAMORPH’s practical exclusivity has already been eroded by the availability of generic morphine sulfate injection products. The exact timing of any remaining branded protection depends on the specific presentation, NDA history, current Orange Book entries, and any later-listed patents.

FDA exclusivity and Orange Book implications

For an established morphine sulfate injection, the relevant questions are:

1. Is the reference listed drug still active in the Orange Book?
2. Are any patents listed against the specific strength or dosage form?
3. Does the proposed generic match the reference product’s route, strength, dosage form, and inactive ingredients?
4. Is a Paragraph IV certification required?
5. Does the proposed product use a different device or formulation that requires a 505(b)(2) application?

FDA Orange Book patent listings determine whether an ANDA applicant must make a Paragraph IV certification or another certification under section vi of the patent certification framework [2]. An old injectable product can remain commercially difficult to copy even without patent protection because of sterile manufacturing requirements and low-margin hospital pricing.

Which companies are challenging or competing with DURAMORPH?

Competition comes primarily from generic morphine sulfate injection manufacturers rather than from biosimilar developers. Morphine is a small-molecule opioid, so biosimilar legislation and biologic interchangeability rules do not apply.

Relevant competitive categories include:

Competitor type	Examples of commercial positioning
Generic injectable manufacturers	Morphine sulfate injection in preservative-free or product-specific presentations
Branded legacy products	DURAMORPH and other hospital-distributed morphine presentations
Compounded sterile pharmacies	Patient-specific or institution-specific preparations, subject to applicable law
Hospital pharmacy operations	Internal preparation from approved bulk or commercial injectable products
Alternative opioids	Hydromorphone, fentanyl, sufentanil, and other perioperative analgesics
Delivery-system companies	Intrathecal pumps, epidural systems, and prefilled syringe platforms

Competition is determined by availability, concentration, route labeling, shortage status, wholesaler service levels, and contract pricing. A product with modest technical differentiation can gain share if it reduces pharmacy manipulation or avoids recurring supply interruptions.

What generic entry risks exist for DURAMORPH?

Generic entry risk is high for the active ingredient but moderate for the complete commercial product.

Regulatory risks

An ANDA applicant must address:

• Pharmaceutical equivalence
• Bioequivalence or applicable product-specific requirements
• Same dosage form and route
• Sterility assurance
• Container-closure performance
• Inactive-ingredient differences
• Labeling conformity
• Controlled-substance controls
• Manufacturing-site inspection readiness

For neuraxial products, excipient differences can create added scrutiny. Even when an excipient is generally recognized as safe for injection, its suitability for intrathecal or epidural administration must be supported by route-specific evidence and product labeling.

Manufacturing and supply risks

Sterile morphine products require validated aseptic processing or terminal sterilization where feasible, environmental monitoring, media fills, container-closure integrity testing, and robust deviation management. Glass ampules may reduce some permeability concerns but introduce breakage and withdrawal challenges. Polymer syringes improve convenience but create greater interaction and extractables questions.

The highest-value manufacturing barrier is reliable sterile capacity. A generic company with an established injectable platform can often compete more effectively than a drug developer with no sterile operations.

What patent litigation affects DURAMORPH?

No active patent-litigation strategy should be presumed to protect the legacy DURAMORPH product. The key legal disputes for a new entrant would more likely involve:

• Patent certification under the Hatch-Waxman framework
• Device or prefilled-syringe patents
• Formulation patents covering a novel concentration or stabilizer system
• Method-of-use patents for a defined neuraxial dosing protocol
• Trade-secret or manufacturing disputes
• Product-liability and controlled-substance compliance issues

A conventional preservative-free morphine sulfate injection is unlikely to support a durable patent position unless it includes a genuinely novel formulation, delivery device, or clinically meaningful use. Broad claims directed to morphine sulfate in Water for Injection and sodium chloride would face substantial validity and prior-art challenges.

How strong is the DURAMORPH patent estate?

The legacy patent estate is commercially weak compared with newer branded injectables. The likely strength profile is:

Patent dimension	Relative strength
Active ingredient	Very low
Basic injectable solution	Low
Preservative-free positioning	Low to moderate, depending on claim scope
Neuraxial use	Low for broad claims; potentially stronger for narrow dosing or patient-selection claims
Prefilled syringe or device	Moderate if supported by specific engineering claims
Manufacturing process	Moderate if the process is difficult to replicate and properly claimed
Trade secrets and quality systems	Commercially meaningful but not patent exclusivity

The defensible opportunity is therefore a narrow, technically supported improvement. Examples include a validated ready-to-administer syringe, a concentration-specific error-reduction presentation, or a container system that improves stability and reduces preparation waste.

What commercial opportunities exist for DURAMORPH excipient innovation?

Ready-to-administer neuraxial products

Hospitals may pay for products that reduce pharmacy preparation, labeling, compounding, and waste. A prefilled, preservative-free syringe could support premium pricing if it improves workflow without compromising dosing flexibility.

Strength differentiation

Morphine injection products can create selection risks when multiple concentrations are stocked together. Distinct carton design, unit-dose presentation, barcode controls, and standardized fill volumes may reduce selection errors. The commercial claim must be based on validated human-factors evidence rather than packaging aesthetics alone.

Supply continuity

Hospital buyers often value dependable availability more than minor formulation differences. A manufacturer with dual-source raw materials, redundant filling capacity, and strong controlled-substance logistics can win tenders even with a conventional formulation.

Low-waste formats

Single-dose ampules may generate product waste when the full contents are not required. Smaller unit doses, prefilled syringes, or coordinated concentration portfolios can reduce waste and simplify inventory management.

Geographic expansion

The excipient strategy must account for jurisdictional differences in approved routes, preservative requirements, container standards, labeling, and controlled-substance regulation. A formulation accepted for intravenous use in one market may require separate justification for epidural or intrathecal use elsewhere.

How does DURAMORPH compare with alternative opioid products?

DURAMORPH competes with other opioids on analgesic potency, duration, administration route, safety monitoring, supply, and price.

Product category	Excipient and formulation opportunity	Competitive limitation
Morphine sulfate injection	Simple preservative-free solution; ready-to-use presentation	Established generic competition
Hydromorphone injection	Strength and syringe differentiation	Higher potency creates dosing-risk concerns
Fentanyl injection	Low-volume presentation and device integration	Shorter duration and different clinical profile
Sufentanil injection	Specialty anesthesia positioning	Smaller addressable market
Liposomal or extended-release opioids	Complex formulation differentiation	Higher development and regulatory cost

DURAMORPH’s strongest niche is neuraxial morphine where clinicians value a recognized product and a preservative-free presentation. Its weakness is limited chemical differentiation and substantial generic substitutability.

What is the FDA regulatory status of DURAMORPH?

DURAMORPH is an FDA-approved morphine sulfate injectable product marketed for specified neuraxial uses under its approved labeling [1]. The product is subject to controlled-substance requirements, sterile injectable manufacturing standards, and route-specific labeling controls.

A new conventional generic would generally pursue an ANDA. A differentiated formulation, device, concentration, or delivery system may require a 505(b)(2) application. The choice affects clinical requirements, patent certifications, exclusivity potential, and time to approval.

FDA drug shortages and the availability of approved injectable morphine products should be monitored because supply disruptions can change the commercial value of a new presentation. The FDA Drug Shortages database is the relevant source for current shortage status [3].

Key Takeaways

• DURAMORPH is a preservative-free morphine sulfate injection for neuraxial administration.
• Its formulation strategy is intentionally simple: Water for Injection, sodium chloride where required, and no antimicrobial preservative.
• The main commercial barriers are sterile manufacturing, route-specific quality, controlled-substance compliance, and hospital supply reliability.
• The legacy product is unlikely to have meaningful active-ingredient patent protection.
• Generic entry risk is high, but a ready-to-administer presentation can support differentiation.
• Prefilled syringes, low-waste packaging, barcode-enabled unit doses, and concentration-specific safety design are the strongest commercial opportunities.
• A conventional formulation is generally an ANDA opportunity; a new device or delivery system may require a 505(b)(2) pathway.
• Biosimilar competition is not relevant because morphine sulfate is a small molecule.
• Any current patent or Paragraph IV assessment must be tied to the specific reference-listed drug, strength, dosage form, and Orange Book entry.

FAQs

Can benzyl alcohol be added to a DURAMORPH-like product?

A benzyl alcohol formulation would create significant route-specific safety and regulatory concerns for epidural or intrathecal administration. A preservative-free design is commercially and clinically preferable.

Is sodium metabisulfite suitable for preservative-free morphine injection?

It may reduce oxidation in some injectable systems, but it adds route-specific toxicology, labeling, and compatibility questions. It should not be used unless degradation data establish a clear need and the product is appropriate for the intended route.

Would a prefilled DURAMORPH syringe receive new regulatory exclusivity?

A prefilled syringe may support device, formulation, or method-of-use patents and could qualify for regulatory benefits depending on the application. The packaging change alone does not guarantee meaningful exclusivity.

Can a 505(b)(2) product claim intrathecal use for a new morphine formulation?

Potentially, but the sponsor must establish that the formulation, device, concentration, or administration profile is sufficiently supported for the proposed route and indication. The existing DURAMORPH label cannot automatically support every modified product.

What is the most attractive commercial excipient opportunity?

The most practical opportunity is a low-excipient, preservative-free morphine sulfate solution in a validated ready-to-administer syringe. The value comes from workflow reduction, dosing control, and supply reliability rather than from a novel chemical excipient.

References

1. U.S. Food and Drug Administration. (n.d.). DURAMORPH (morphine sulfate injection, USP) prescribing information.
2. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: The Orange Book.
3. U.S. Food and Drug Administration. (n.d.). Drug shortages database.
4. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.
5. U.S. Food and Drug Administration. (2019). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin.